Simplified overview of the strategy that can be drawn from the data of Hrusak et al. HR, high risk; MLL, mixed-lineage leukemia; MRD, minimal residual disease; PPR, prednisone poor responder. *iCD3 and CD7⁺ or ≥2 of CD10, ICD79a, or iCD22⁺. Lymphoblast picture by courtesy of Isabelle Sudaka, Hematology Laboratory, CHU de Nice, France.